Fulvestrant
- Generic Name
- Fulvestrant
- Brand Names
- Faslodex, Fulvestrant Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47F5O3S
- CAS Number
- 129453-61-8
- Unique Ingredient Identifier
- 22X328QOC4
- Background
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatme...
- Indication
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
- Associated Therapies
- -
MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer
- First Posted Date
- 2011-04-28
- Last Posted Date
- 2018-07-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 31
- Registration Number
- NCT01344031
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-04-20
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 31
- Registration Number
- NCT01339442
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women
- First Posted Date
- 2011-02-21
- Last Posted Date
- 2015-04-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 249
- Registration Number
- NCT01300351
- Locations
- 🇨🇳
Research Site, Tianjin, China
A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-02-15
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 674
- Registration Number
- NCT01296555
- Locations
- 🇺🇸
Univ of Chicago, Chicago, Illinois, United States
🇺🇸Mary Crowley Cancer Rsch Ctr, Dallas, Texas, United States
🇺🇸Baylor Sammons Cancer Center, Dallas, Texas, United States
A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene
- Conditions
- Interventions
- First Posted Date
- 2010-10-13
- Last Posted Date
- 2020-09-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 221
- Registration Number
- NCT01219699
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇬🇧Novartis Investigative Site, Oxford, United Kingdom
🇺🇸Vanderbilt Univeristy SC, Nashville, Tennessee, United States
Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2010-09-16
- Last Posted Date
- 2016-02-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 127
- Registration Number
- NCT01202591
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Role of Endogenous Estrogen in Growth-Hormone Regulation in Postmenopausal Women
- First Posted Date
- 2010-08-23
- Last Posted Date
- 2015-03-27
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 30
- Registration Number
- NCT01186796
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy
- First Posted Date
- 2010-07-12
- Last Posted Date
- 2019-05-15
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 46
- Registration Number
- NCT01160718
- Locations
- 🇨🇭
Kantonsspital Aarau, Aarau, Switzerland
🇨🇭Kantonsspital Baden, Baden, Switzerland
🇨🇭City Hospital Triemli, Zurich, Switzerland
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
- First Posted Date
- 2010-06-11
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 118
- Registration Number
- NCT01142401
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸Yale University, New Haven, Connecticut, United States
🇺🇸Maimonides Medical Center, Brooklyn, New York, United States
Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)
- Conditions
- Interventions
- First Posted Date
- 2009-07-23
- Last Posted Date
- 2011-08-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 25
- Registration Number
- NCT00944918
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.